The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to interact with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. Ectopic expression of this gene was shown to suppress the growth of human cells in a manner that appears to correlate with the presence of a wild-type RB1 function. Studies in the knockout mice suggested the roles of this gene in regulating spermatogenesis, as well as in suppressing tumorigenesis. Two alternatively spliced transcript variants of this gene, which encode an identical protein, have been reported.[7]
^Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C (July 1998). "Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer". Biochem. Biophys. Res. Commun. 247 (1): 146–53. doi:10.1006/bbrc.1998.8497. PMID9636670. S2CID38236434.
^ abEwing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L, Robinson MD, O'Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A, Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J, Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogue K, Colwill K, Gladwish K, Muskat B, Kinach R, Adams SL, Moran MF, Morin GB, Topaloglou T, Figeys D (2007). "Large-scale mapping of human protein-protein interactions by mass spectrometry". Mol. Syst. Biol. 3 (1): 89. doi:10.1038/msb4100134. PMC1847948. PMID17353931.
Ghosh PK, Anderson J, Cohen N, Takeshita K, Atweh GF, Lebowitz P (1993). "Expression of the leukemia-associated gene, p18, in normal and malignant tissues; inactivation of expression in a patient with cleaved B cell lymphoma/leukemia". Oncogene. 8 (10): 2869–72. PMID8397372.
Lapointe J, Lachance Y, Labrie Y, Labrie C (1996). "A p18 mutant defective in CDK6 binding in human breast cancer cells". Cancer Res. 56 (20): 4586–9. PMID8840966.
Venkataramani R, Swaminathan K, Marmorstein R (1998). "Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations". Nat. Struct. Biol. 5 (1): 74–81. doi:10.1038/nsb0198-74. PMID9437433. S2CID20199775.
Iolascon A, Giordani L, Moretti A, Basso G, Borriello A, Della Ragione F (1998). "Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma". Hepatology. 27 (4): 989–95. doi:10.1002/hep.510270414. PMID9537438. S2CID29827217.
Noh SJ, Li Y, Xiong Y, Guan KL (1999). "Identification of functional elements of p18INK4C essential for binding and inhibition of cyclin-dependent kinase (CDK) 4 and CDK6". Cancer Res. 59 (3): 558–64. PMID9973200.
Li J, Byeon IJ, Ericson K, Poi MJ, O'Maille P, Selby T, Tsai MD (1999). "Tumor suppressor INK4: determination of the solution structure of p18INK4C and demonstration of the functional significance of loops in p18INK4C and p16INK4A". Biochemistry. 38 (10): 2930–40. CiteSeerX10.1.1.386.342. doi:10.1021/bi982286e. PMID10074345.
Schreiber M, Muller WJ, Singh G, Graham FL (1999). "Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity". Oncogene. 18 (9): 1663–76. doi:10.1038/sj.onc.1202466. PMID10208428. S2CID26097115.
Korshunov A, Golanov A (2002). "Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: correlation with tumor grade and clinical outcome". Arch. Pathol. Lab. Med. 126 (1): 42–8. doi:10.5858/2002-126-0042-IAOPAP. PMID11800646.
Arcellana-Panlilio MY, Egeler RM, Ujack E, Magliocco A, Stuart GC, Robbins SM, Coppes MJ (2002). "Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors". Genes Chromosomes Cancer. 35 (2): 176–81. doi:10.1002/gcc.10108. PMID12203782. S2CID27477191.